文献速递膀胱癌与上尿路尿路上皮癌

帕博利珠单抗新辅助治疗后残留膀胱癌的分子特征

Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
PubMed 文献 · Eur Urol · 2021-03-28

该研究对26例帕博利珠单抗治疗后行根治性膀胱切除术的肌层浸润性尿路上皮癌标本进行转录组表达谱分析,其中22例有匹配的治疗前样本。无监督共识聚类显示三个亚型:基底型、管腔型和瘢痕样型,瘢痕样型占50%且表达创伤愈合相关基因。仅36%的样本治疗前后亚型一致,瘢痕样亚型在系统治疗后有良好预后,但在单纯膀胱切除术中未见此优势。

要点

  • 帕博利珠单抗治疗后残留肿瘤中瘢痕样亚型占50%,表达创伤愈合相关基因
  • 治疗前后分子亚型一致性仅36%,提示治疗可诱导或选择亚型改变
  • 瘢痕样亚型在系统治疗后预后良好,但单纯手术队列中无此优势

核心结论

  • 帕博利珠单抗耐药MIBC存在基底型、管腔型和瘢痕样型三种分子亚型,瘢痕样型占50%。
  • 治疗前后分子亚型一致性低(36%),提示免疫治疗可能选择或诱导管腔表型。
  • 瘢痕样亚型在系统治疗后预后良好,但在单纯膀胱切除术中未见预后优势。

研究设计与样本

  • 对26例帕博利珠单抗治疗后ypT2-4期根治性膀胱切除标本行转录组表达谱分析,其中22例有匹配治疗前样本。
  • 将26例治疗后样本与94例未接受新辅助治疗的根治性膀胱切除样本及21例新辅助化疗后瘤床瘢痕组织样本进行无监督共识聚类比较。
  • 聚类结果与133例新辅助化疗后肿瘤队列进行比较,主要终点为无复发生发生存。

主要发现

  • 治疗前后样本分子亚型一致性仅36%。
  • 无监督共识聚类识别出三个帕博利珠单抗治疗后聚类:基底型、管腔型和瘢痕样型。
  • 瘢痕样亚型占帕博利珠单抗治疗后病例的50%(n=13),表达创伤愈合/瘢痕相关基因。
  • 帕博利珠单抗治疗后瘢痕样亚型相比其他队列的瘢痕样肿瘤,管腔标志物表达更高。
  • 瘢痕样亚型患者在系统治疗后预后良好,但在单纯根治性膀胱切除队列中未显示预后优势。

关键数值与推荐

  • 分子亚型一致性定义为共识分类器判定的治疗前后亚型相同,仅36%样本符合。
  • 瘢痕样亚型在帕博利珠单抗治疗后占50%(n=13),表达创伤愈合/瘢痕相关基因。
  • 瘢痕样亚型在帕博利珠单抗治疗后管腔标志物表达高于其他队列的瘢痕样肿瘤。

临床怎么用

  • 帕博利珠单抗治疗后残留肿瘤分子亚型常发生改变,需重新评估生物学特征。
  • 瘢痕样亚型在系统治疗后预后良好,或可辅助个体化治疗策略制定。
  • 管腔型肿瘤可能对免疫治疗耐药,或免疫治疗可选择/诱导管腔表型。

局限性

  • 各亚组样本量小是本研究的主要局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with muscle-invasive urothelial bladder cancer (MIBC), molecular alterations in immunotherapy-resistant tumors found at radical cystectomy (RC) remain largely unstudied. OBJECTIVE: To investigate the biology of pembrolizumab-resistant tumors in comparison to an RC cohort treated without any systemic therapy and a cohort of neoadjuvant chemotherapy (NAC)-treated tumors. DESIGN, SETTING, AND PARTICIPANTS: Transcriptome-wide expression profiling was performed on 26 RC samples from patients with ypT2-4 disease after pembrolizumab treatment, of which 22 had matched pretherapy samples. Unsupervised consensus clustering (CC) was performed to compare 26 post-pembrolizumab samples with 94 RC samples without neoadjuvant treatment and 21 samples collected from the former tumor bed of NAC-treated patients (scar tissue). Clusters were investigated for their biological and clinical characteristics and were compared to a cohort of post-NAC tumors (n = 133). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patient and tumor characteristics were compared between subgroups using χ2 tests and two-sided Wilcoxon rank-sum tests. The primary endpoint was recurrence-free survival. RESULTS AND LIMITATIONS: Molecular subtyping of pre- and post-pembrolizumab samples revealed significant differences: only 36% of samples had a concordant subtype according to the consensus classifier. Unsupervised CC revealed three distinct post-pembrolizumab clusters (basal, luminal, and scar-like). A scar-like subtype was present in 50% of the post-pembrolizumab cases (n = 13) and expressed genes associated with wound healing/scarring. This subtype had higher luminal marker expression in the post-pembrolizumab setting compared to CC scar-like tumors from the other cohorts. Patients with the scar-like subtype showed favorable prognosis after systemic therapy, but not in the RC-only setting. The small numbers in each subgroup represents the major study limitation. CONCLUSIONS: This study expands our understanding of the biology of pembrolizumab-resistant MIBC and provides a framework for defining molecular subtypes after treatment. The results further support the hypothesis that luminal-type tumors may be resistant to immunotherapy or that this treatment may select for, or induce, a luminal phenotype. PATIENT SUMMARY: We carried out genetic analysis for bladder cancer tumors from patients who had received an immunotherapy agent called pembrolizumab and compared them to tumors treated with standard chemotherapy or just bladder removal. We found differences in gene expression between the treatment types and between tumor tissue from the same patient before and after treatment. These results may be helpful in personalizing therapy strategies for patients with bladder cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Necchi A, de Jong JJ, Raggi D, et al. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. Eur Urol. 2021. PMID: 33785257. doi:10.1016/j.eururo.2021.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。